Dartmouth Health is the only health care system on the East Coast to be part of the newly launched Brain Health Navigator ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...

The Davos Alzheimer’s Collaborative (DAC), a pioneering worldwide initiative seeking to cure Alzheimer’s disease and improve ...

The researchers found the presence of CMV antibodies all over patients with Alzheimer's disease, including the intestines, ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Activation of SIGMAR1 is expected to restore cellular homeostasis by inducing autophagy, which may slow neurodegeneration in patients with early AD.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain ...